Connect with us

CBD News

New Ipsos Cannabis Study Reveals Majority Of Canadians In Workplace Are Not High

Jane Summers

Published

on

New-Study-on-Cannabis-in-the-Canadian-Workplace
- Ad -

ADP Canada commissioned a study from Lpsos to determine the state of recreational marijuana in the workplace. According to the press release discussing the study, it was found that the majority of workplaces in the country do not permit recreational cannabis before, during, and after work.

No matter though, because 75% of respondents also believed that

“Cannabis has had no impact at work in terms of health and safety incidents, productivity (74%), absenteeism (71%) or quality of work (70%).”

Further, for the employers who do permit the use of recreational cannabis before or after work, 63% of survey respondents reported that they consume it before work, 47% consumed it during work hours, and 72% consumed it after work. The press release also indicates, though, that “when looking at Canada’s working population at large, the survey finds that only a fraction of Canadians consume recreational cannabis before work (5%), during work hours (4%) and after work with colleagues (6%).

Hendrik Steenkamp, the Director, HR Advisory, of ADP Canada, stated in the press release,

“There was a lot of uncertainty and hype leading up to cannabis legalization last year, but so far, cannabis has not had a noticeable impact on the workplace or on workplace performance. Although only a fraction of Canadian workplaces allow cannabis during the workday, it's important for every organization to develop proper workplace guidelines and policies, as well as provide training to identify and manage impairment.”

The press release also indicates that attitudes concerning recreational cannabis has not changed significantly since the substance was legalized. About half of survey participants “claim their perception of cannabis has not changed at all and 22 per cent say their perception of cannabis is more positive.”

In addition, it is possible that due to legalization in Canada, there may be changes among workplace policies and practices concerning cannabis use. Survey respondents indicated (55%) that they do not expect that impending legalization will change their employer’s expectations concerning impairment.

In the United States, “Medical or recreational marijuana is now legal in 33 U.S. states, even though its possession or use is illegal under federal law. It’s an untenable situation that individuals engaging in an activity that’s now legal in 60 percent of the country are violating federal law. This is problematic for marijuana users, as well as for the cannabis industry,” an article by Stat News reports.

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or medical advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.